Company intelligence / Profile preview
Eikonizo Therapeutics
Cambridge, Massachusetts, USAeikonizo.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead candidate EKZ-102 is in IND-enabling development for ALS treatment with planned expansion to other neurodegenerative disorders
- Therapeutic areas
- CardiovascularNeurology
- Modalities
- Small molecules (brain penetrant and peripheral small molecules)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Novo Nordisk (investment through Science2Medicine iNNvest initiative)
Beyond the preview
Go deeper on Eikonizo Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eikonizo Therapeutics.